Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
|ClinicalTrials.gov Identifier: NCT00126412|
Recruitment Status : Completed
First Posted : August 4, 2005
Last Update Posted : May 16, 2007
|Condition or disease||Intervention/treatment||Phase|
|Pheochromocytoma Neuroblastoma||Drug: 123I-mIBG (meta-iodobenzylguanidine)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||185 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||July 2005|
- - To demonstrate that 123I-mIBG planar scintigraphy is sensitive and specific in confirming or excluding the diagnoses of neuroblastoma and phaeochromocytoma.
- To determine the incremental value of single-photon emission computed tomography (SPECT) for improving the sensitivity and specificity of 123I-mIBG planar scintigraphy for the diagnoses of neuroblastoma and phaeochromocytoma.
- To collect safety data on 123I-mIBG.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00126412
|United States, New Jersey|
|Princeton, New Jersey, United States, 08540|
|Study Director:||Diane McCaul||GE Healthcare|